Janux Therapeutics, Inc.·4

Apr 23, 8:00 PM ET

Meyer Andrew Hollman 4

4 · Janux Therapeutics, Inc. · Filed Apr 23, 2025

Insider Transaction Report

Form 4
Period: 2025-04-21
Meyer Andrew Hollman
Chief Business Officer
Transactions
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-04-213,33490,665 total
    Exercise: $4.21Exp: 2031-03-09Common Stock (3,334 underlying)
  • Exercise/Conversion

    Common Stock

    2025-04-21$4.21/sh+3,334$14,03685,473 total
  • Sale

    Common Stock

    2025-04-21$30.00/sh3,334$100,02082,139 total
Footnotes (2)
  • [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
  • [F2]Immediately exercisable.

Documents

1 file
  • 4
    form4-04232025_080401.xmlPrimary